Shots:

• The P-II ZUMA-5 trial assessing Yescarta in 146 patients aged ≥18rs. with r/r iNHL include FL- prior treated with at least 2L of systemic therapy
• Results: 94% of patients achieved a response @18mos.- & 2EPs of mPFS and OS were not yet reached. In a weighted analysis- the results compared with ZUMA-5 patients vs SCHOLAR-5 patients- therapy showed superior OS & PFS over currently available treatments
• Patients achieved a response (94% vs 50%) @median follow-up of 26.2 mos.- reduction in risk of disease progression (58% vs 70%)- relapse or death vs current therapies in a control cohort- m-PFS & OS (12.7 & 59.8 mos.) in a control cohort- respectively

  | Ref: Business Wire | Image: Business Wire